Phase 3 Trial of PROTHROMPLEX TOTAL for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoag

The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagulation reversal in participants treated with Factor Xa inhibitors who require urgent surgery/invasive procedure.

The participant will be assigned by chance to either TAK-330 or SOC 4F-PCC as part of standard treatment before surgery.

Patients participating in this study will need to be hospitalized. They will also be contacted (via telehealth/phone call) 30 days after the surgery.

Inclusion Criteria:

• Participant or legally authorized representative willing to sign e-consent/written informed consent form.

• Participants at least 18 years of age at enrollment.

• Participant currently on treatment with oral Factor Xa inhibitor (rivaroxaban, apixaban, edoxaban).

• In the opinion of the surgeon, the participant requires an urgent surgery/procedure that is associated with high-risk of intraoperative bleeding within 15 hours from the last dose of Factor Xa inhibitor and requires a reversal agent for suspected direct oral Factor Xa inhibitor-related coagulopathy. For participants who are beyond the 15-hour window, eligibility requires proof of elevated plasma anti Factor Xa (FXa) levels using either specific direct oral anti-coagulant (DOAC)-calibrated (apixaban, rivaroxaban or edoxaban) anti-FXa levels of greater than (>) 75 nanograms per milliliter (ng/mL), or heparin calibrated anti-FXa assay levels of >0.5 international unit per milliliter (IU/mL) at screening.

• Women of childbearing potential should have a negative pregnancy test documented prior to enrollment.

Exclusion Criteria:

• The participant has an expected survival of less than 30 days, even with best available medical and surgical care.

• Recent history (within 90 days prior to screening) of venous thromboembolism, myocardial infarction (MI), disseminated intravascular coagulation (DIC), ischemic stroke, transient ischemic attack, hospitalization for unstable angina pectoris or severe or critical coronavirus 2 (SARS-CoV-2) infection.

• Active major bleeding defined as bleeding that requires surgery or transfusion of >2 units of packed red blood cell (PRBC) or intracranial hemorrhage with the exception of subacute and chronic subdural hemorrhages with a Glasgow Coma Score (GCS) greater than or equal to (>=) 9.

• Polytrauma for which reversal of Factor Xa-inhibition alone would not be sufficient to achieve hemostasis.

• Known prothrombotic disorder including primary antiphospholipid syndrome, antithrombin-3 deficiency, homozygous protein C deficiency, homozygous protein S deficiency, and homozygous factor V Leiden.

• Known bleeding disorder (eg, platelet function disorders, hemophilia, Von Willebrand disease, or coagulation factor deficiency).

• Platelet count less than (=65 millimeters of mercury (mmHg) and having blood lactate >2 millimole (mmol) despite adequate volume resuscitation.

• Acute or chronic liver failure (hepatic cirrhosis Child-PUGH score C)

• Renal failure requiring dialysis

• Any other condition that could, in the opinion of the investigator, put the participant at undue risk of harm if the participant were to participate in the study.

• Participation in another clinical study involving an investigational product or device within 30 days prior to study enrollment, or planned participation in another clinical study involving an investigational product or device during the course of this study.

• The use of PROTHROMPLEX TOTAL as SOC 4F-PCC.

• Women who are breastfeeding at the time of enrollment .